PAVmed Inc. (PAVM)
| Market Cap | 557.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.42M |
| Shares Out | 82.24M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,297,343 |
| Open | 6.67 |
| Previous Close | 6.58 |
| Day's Range | 6.04 - 6.70 |
| 52-Week Range | 1.63 - 9.70 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+56.3%) |
| Est. Earnings Date | Nov 4, 2021 |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusi...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 9.50, which is an increase of 56.25% from the latest price.
News
PAVM Stock: One Big Reason Why PAVmed Is Plunging Today
Today, a relatively disappointing start to trading for a PAVmed subsidiary, Lucid Diagnostics, is driving some bearish price action. The post PAVM Stock: One Big Reason Why PAVmed Is Plunging Today appe...
Lucid Diagnostics Announces Pricing of Initial Public Offering
NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics announces pricing of Initial Public Offering.
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...
PAVmed to Host Digital Health Virtual Investor Event
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed to Host Digital Health Virtual Investor Event, Veris Health: Bringing Digital Health to Cancer Care.
Why PAVmed Shares Are Trading Higher Today
PAVmed Inc (NASDAQ: PAVM) is trading higher Thursday after the company announced its majority-owned subsidiary, Lucid Diagnostics, filed a registration statement for a proposed initial public offering. ...
These 2 Nasdaq Small Caps Just Got Big Boosts
In a rising market, these companies looked especially impressive.
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary, Lucid Diagnostics, files registration statement for proposed initial public offering.
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development P...
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Veris Health joins Microsoft for startups global program and engages Loka as software development partner.
PAVmed to Participate in September Investor and MedTech Conferences
NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed to participate in September investor and MedTech conferences.
Why Shares of PAVmed Were Down This Morning
Investors are growing impatient about a planned spinoff.
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Lucid Diagnostics launches first Lucid test centers. Patients undergoing esophageal precancer testing in Phoenix metro area.
PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference
NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed's CEO, Lishan Aklog, will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT
Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors
NEW YORK--(BUSINESS WIRE)---- $PAVM--Prominent global industry executive Aster Angagaw has joined the Board of Directors of PAVmed's subsidiary, Lucid Diagnostics Inc.
CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
NEW YORK--(BUSINESS WIRE)---- $pavm #earnings--PAVmed to hold business update conference call on August 12, 2021. Company conference call and webcast at EDT 4:30PM EDT.
PAVmed to Hold Business Update Conference Call on August 12, 2021
NEW YORK--(BUSINESS WIRE)---- $pavm #earnings--PAVmed to hold business update conference call on August 12, 2021. Company conference call and webcast at EDT 4:30PM EDT.
3 Biotech Penny Stocks To Watch On Robinhood IPO Day
These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
Why PAVmed Soared by 12% on Wednesday
The company tapped a respected figure in its industry as a board vice chairman.
Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vi...
NEW YORK--(BUSINESS WIRE)---- $pavm--Stanley Lapidus, former Chairman & CEO of Exact Sciences, joins PAVmed subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors.
PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScr...
NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed Subsidiary Lucid Diagnostics launches strategic partnership with direct-to-consumer telemedicine company UpScriptHealth.
Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board...
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major ...
PAVmed Launches Digital Health Company Veris Health Inc.
New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc.
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid D...
PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced...